Clinical Trials Browser

Prostatic Neoplasms

NCT03553602 2026-01-29

BEACON

Phase 1/2 Terminated

3 enrolled 7 charts

Genitourinary

Prostatic Neoplasms

NCT05617040 2025-11-10

Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Phase 1/2 Terminated

22 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT03843918 2025-09-10

A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer

Phase 1/2 Terminated

33 enrolled

Genitourinary

Prostatic Neoplasms

NCT05633160 2025-08-29

COMBAT

Phase 1/2 Terminated

4 enrolled

Genitourinary

Prostatic Neoplasms

NCT03712371 2025-06-10

Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients

Phase 1/2 Terminated

12 enrolled 9 charts

Genitourinary

Prostatic Neoplasms

NCT04556617 2025-04-08

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 1/2 Terminated

19 enrolled 11 charts

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT04382898 2025-03-20

PRO-MERIT

Phase 1/2 Terminated

75 enrolled 17 charts

Genitourinary

Prostatic Neoplasms

NCT06257758 2025-03-17

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

Phase 1/2 Terminated

6 enrolled

BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

NCT05075577 2025-02-28

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

Phase 1/2 Terminated

77 enrolled

Genitourinary

Prostatic Neoplasms

NCT05917470 2024-12-11

A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

Phase 1/2 Terminated

21 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT00321698 2024-08-29

Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer

Phase 1/2 Terminated

25 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT06065059 2024-08-13

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Phase 1/2 Terminated

7 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT05553639 2024-06-12

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Terminated

12 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT05716295 2024-05-08

ORCHID-1

Phase 1/2 Terminated

26 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03577028 2024-02-14

Study of HPN424 in Patients With Advanced Prostate Cancer

Phase 1/2 Terminated

104 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT00633087 2023-12-22

2-Deoxyglucose

Phase 1/2 Terminated

12 enrolled 8 charts

Genitourinary

Prostatic Neoplasms

NCT03837353 2023-12-18

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

Phase 1/2 Terminated

18 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT04737109 2023-11-13

ADDItion

Phase 1/2 Terminated

6 enrolled 9 charts

Genitourinary

Prostatic Neoplasms

NCT01093183 2023-09-13

Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

Phase 1/2 Terminated

25 enrolled 8 charts

Genitourinary

Prostatic Neoplasms

NCT05489991 2023-08-18

A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 1/2 Terminated

1 enrolled

Genitourinary

Prostatic Neoplasms

NCT04424641 2023-07-25

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Phase 1/2 Terminated

48 enrolled 20 charts

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Prostatic Neoplasms, Uterine Neoplasms, Triple Negative Breast Neoplasms

NCT03367819 2022-05-16

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Phase 1/2 Terminated

44 enrolled 24 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms

NCT02913131 2022-04-22

Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies

Phase 1/2 Terminated

23 enrolled 6 charts

Genitourinary

Prostatic Neoplasms

NCT03441464 2022-02-25

Feasibility of the LUM Imaging System for Detection of Prostate Cancer

Phase 1/2 Terminated

9 enrolled

Genitourinary

Prostatic Neoplasms, Neoplasm, Residual

NCT02565901 2021-10-01

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Terminated

28 enrolled 8 charts

Genitourinary

Prostatic Neoplasms

NCT03545165 2021-08-24

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

Phase 1/2 Terminated

6 enrolled 24 charts

Genitourinary

Prostatic Neoplasms

NCT02805894 2021-05-10

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

Phase 1/2 Terminated

5 enrolled

Genitourinary

Prostatic Neoplasms

NCT03323879 2021-04-27

Delight

Phase 1/2 Terminated

7 enrolled

Genitourinary

Prostatic Neoplasms

NCT03572478 2021-03-09

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

Phase 1/2 Terminated

12 enrolled 7 charts

GenitourinaryGynecologic

Prostatic Neoplasms, Endometrial Neoplasms

NCT03741712 2021-02-05

A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Phase 1/2 Terminated

9 enrolled

Genitourinary

Prostatic Neoplasms

NCT00757757 2020-12-19

A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

Phase 1/2 Terminated

3 enrolled

Genitourinary

Prostatic Neoplasms

NCT00996502 2019-03-27

Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer

Phase 1/2 Terminated

4 enrolled 2 charts

Genitourinary

Prostatic Neoplasms

NCT01163084 2019-02-28

Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer

Phase 1/2 Terminated

10 enrolled 7 charts

Genitourinary

Prostatic Neoplasms

NCT00924807 2018-12-11

Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer

Phase 1/2 Terminated

4 enrolled 4 charts

Genitourinary

Prostatic Neoplasms

NCT00953576 2018-09-04

KHLAD

Phase 1/2 Terminated

11 enrolled 9 charts

Genitourinary

Prostatic Neoplasms

NCT01335204 2018-07-13

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

Phase 1/2 Terminated

4 enrolled 5 charts

Genitourinary

Prostatic Neoplasms

NCT02606123 2018-03-01

Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Terminated

28 enrolled

Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Prostatic Diseases, Prostatic Neoplasms

NCT00536991 2017-06-14

Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer

Phase 1/2 Terminated

51 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT02483884 2017-03-22

PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

Phase 1/2 Terminated

30 enrolled

Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Neoplasms, Urogenital Neoplasms

NCT01817738 2017-02-17

Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer

Phase 1/2 Terminated

197 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00879619 2017-02-01

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

Phase 1/2 Terminated

4 enrolled 3 charts

Genitourinary

Prostatic Neoplasms

NCT01913197 2017-01-06

Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy

Phase 1/2 Terminated

2 enrolled

Genitourinary

Prostatic Neoplasms

NCT00861471 2016-06-30

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

Phase 1/2 Terminated

24 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT00503984 2016-06-09

A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

Phase 1/2 Terminated

22 enrolled 16 charts

Genitourinary

Pain, Prostatic Neoplasms

NCT02042885 2015-10-20

A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer

Phase 1/2 Terminated

79 enrolled

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Endometrial Neoplasms

NCT00539968 2015-02-05

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

Phase 1/2 Terminated

5 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT00753220 2014-11-04

CRITICAL

Phase 1/2 Terminated

7 enrolled 4 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01020305 2014-10-13

Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer

Phase 1/2 Terminated

5 enrolled 6 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Clinical Trials

CELLO-1

BEACON

Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer

COMBAT

Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

PRO-MERIT

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

ORCHID-1

Study of HPN424 in Patients With Advanced Prostate Cancer

2-Deoxyglucose

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

ADDItion

Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies

Feasibility of the LUM Imaging System for Detection of Prostate Cancer

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

Delight

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer

Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer

Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer

KHLAD

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer

PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

CRITICAL

Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer